Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetes.
Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM): evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.
Glucagon-like peptide 1 regulates sequential and compound exocytosis in pancreatic islet beta-cells.
Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes.
Effect of glucagon-like peptide 1 (7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.
Improved glycaemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1
analogue liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.